POLQ and neoplasm: As novel agents are developed, such as the relatively recent and promising DNA polymerase theta (PolQ) inhibitors [183], an improved understanding of the nuances of tumor biology and immunobiology is needed to create biology-driven combinations of therapies that will provide the greatest benefits to patients.